|
|
Ritonavir (Norvir) Research
- Among Patients on Boosted-PI Regimens, Dose Staggering and Selective Non-Adherence to Ritonavir Is Relatively Common (February 6, 2008)
From The Body PRO
- Short-Term Ritonavir Exposure Impacts HDL, CD36 and Triglyceride Levels in Healthy Volunteers (February 4, 2008)
Marta Boffito, M.D., Ph.D., discusses her study, which examines the possible role of ritonavir in increasing cardiovascular risk.
From The Body PRO
- Notice of Important New Drug Interactions With Norvir, Kaletra (March 30, 2005)
New interactions noted with fluticasone (a component of Flonase nasal spray) and trazodone (Desyrel, an antidepressant).
From U.S. Food and Drug Administration
- Drug Development News: Abbott (May/June 2004)
New formulations of lopinavir/ritonavir (Kaletra) and ritonavir are in the works.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Abbott Laboratories Increases Norvir Price Fivefold (December 26, 2003)
John James analyzes the factors that may have played a role in the price hike.
In AIDS Treatment News, from AIDS Treatment News
- Pharmacological and Therapeutic Properties of Ritonavir-Boosted Protease Inhibitor Therapy in HIV-Infected Patients (December 4, 2003)
In Journal of Antimicrobial Chemotherapy
- Ritonavir Has Anti-Cancer Effects (March 12, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Research From the 42nd ICAAC: Extra Ritonavir: Boost or Consequences (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Low-Dose Ritonavir Moderately Enhances Nelfinavir Exposure (October 2002)
An abstract from Clinical Pharmacology & Therapeutics.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Ritonavir Can Reduce Kaposi's Sarcoma Risk (July 18, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Efficacy and Safety of Amprenavir/Ritonavir 600/100 mg BID Compared to APV 1,200 mg BID in ART-Experienced and Naive Subjects: ESS40011 (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Preliminary Results of Intensification Therapy With Amprenavir/Ritonavir in Two Different Doses: 1,200/200 QD vs. 600/100 BID in Heavily Pretreated Patients Failing HAART (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (July 8, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Protease Inhibitors Compared: Studies Examine Dosing, Cholesterol Levels Among Patients Using Fortovase, Invirase (June/July 2002)
In Positive Living, from AIDS Project Los Angeles
- A New Look at Liver Toxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV (March 11, 2002)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination With Efavirenz (EFV) in Healthy Adult Subjects (APV10010) (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Low-Dose Ritonavir (Norvir): Does It Cause PI Drug Resistance? (Winter 2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- In Vitro Model for Antiviral Activity for Amprenavir (APV)/Ritonavir (RTV) (December 19, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Efficacy, Safety and Amprenavir: Pharmacokinetic Responses of Twice-Daily APV and Ritonavir Regimens in HIV-1 Infected Treatment-Experienced Adults for 48 Weeks (ESS40006) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Amprenavir (APV) Plasma and Intracellular Concentrations When Co-Administered With Ritonavir (RTV) in Twice- and Once-Daily Regimens in HIV-Infected Patients (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Drug Interaction: Ritonavir and Fluticasone (November 2001)
Possible link found to Cushing's Syndrome.
In HIV Treatment ALERTS!, from The Center for AIDS
- Ingrown Toenails Still a Possible Side Effect (November 2001)
Indinavir-ritonavir interaction is possible culprit.
In HIV Treatment ALERTS!, from The Center for AIDS
- A Phase IV Randomized Open-Label Multicenter Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg BID) vs. Saquinavir/Ritonavir (1,000/100 mg BID) in Adult HIV-1 Infection: The Max Cmin 1 Trial (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Minor Interaction Between Efavirenz and Saquinavir When Combined With Small Doses of Ritonavir in a QD Regimen (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Abacavir, Lamivudine and Amprenavir +/- Ritonavir Is a Potent and Well-Tolerated HAART Regimen in Therapy-Naive Subjects (Preliminary Results from GW Protocols) (COL30325) (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Influence of 50 mg, 100 mg and 200 mg of Ritonavir (RTV) on the Pharmacokinetics (PK) of Amprenavir (APV) After Multiple Doses in Healthy Volunteers for Once-Daily (QD) and Twice-Daily (BID) Regimens (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Tolerability and Antiviral Activity of Fortovase Plus Ritonavir (May 2001)
In HEPP News, from Brown Medical School
- From Grapefruit Juice to Ritonavir (March 15, 2001)
From Canadian AIDS Treatment Information Exchange
- Protease Combinations: Ritonavir and Indinavir One Year Later (March 15, 2001)
Developments from the 8th Conference on Retroviruses and Opportunistic Infections.
From Canadian AIDS Treatment Information Exchange
- Indinavir/Ritonavir Versus Indinavir in Combination With AZT/3TC for Treatment of HIV in Nucleoside-Experienced Patients: A Randomized, Open-Label Trial (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Preliminary Results From Indinavir (IDV) and Ritonavir (RTV) in a Once-Daily Regimen (Marck 103/104) (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Protease Inhibitor Boosting Enhances Saquinavir Therapy (January 2001)
Highlights from ICAAC 2000.
In Body Positive
- Is Once Daily Indinavir With Ritonavir On the Way? (December 20, 2000)
From Canadian AIDS Treatment Information Exchange
- Abacavir vs. Indinavir in Therapy-Naive People (CNA3014) (August 17, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Ritonavir Intensification of Indinavir in People Without Complete HIV Suppression (August 17, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Therapeutic Drug Monitoring of Amprenavir Combined With Ritonavir as Salvage Therapy in HIV-1-Infected Patients (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Liver Toxicity, Ritonavir, and Hepatitis C: New Data Published (January 21, 2000)
From AIDS Treatment News
- Ritonavir-Saquinavir Combination Therapy in Patients with Advanced HIV Infection (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
|
